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dominated vemurafenib. For sensitivity analysis, 95% of the variance was accounted 
for by health state utilities and cost of dabrafenib. ConClusions: Dabrafenib is the 
most cost-effective treatment for metastatic melanoma in patients with BRAFV600 
mutation given our assumptions. Given the similar QALYs and side effects profile of 
dabrafenib and vemurafenib, but higher drug cost of vemurafenib, a 25% price reduc-
tion for vemurafenib could bring this drug into the cost-effective range. A specific 
decrease of 63% in utility of progression on dabrafenib or a minimum decrease of 
28% for utility of stable disease on dabrafenib is needed to make vemurafenib the 
most cost-effective option.
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Cost-EffECtivENEss of AfAtiNib, ErlotiNib, ANd CisPlAtiN/PEmEtrExEd 
for first-liNE trEAtmENt of mEtAstAtiC Egfr-mutAtioN PositivE NoN-
smAll CEll luNg CANCEr
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objeCtives: To evaluate the cost-effectiveness of afatinib, erlotinib, and cis-
platin/pemetrexed chemotherapy, for first-line treatment of metastatic EGFR-
mutation positive non-small cell lung cancer (NSCLC). Methods: A Markov 
model simulated the lifetime progression of EGFR-mutation positive stage IIIB/
IV NSCLC patients, under each treatment option, from a US societal perspective. 
Probabilities, survival rates and health utilities were obtained from clinical trials 
(LUX-3, LUX-6, EURTAC and OPTIMAL) and published literature. Progression-free 
and overall survival in the erlotinib trial were adjusted up to account for differ-
ences in poorer ECOG performance status compared to the afatinib trial. Costs 
included those for drugs, progression, and side effects in 2013 USD. Expected 
QALYS were calculated. The impact of varying parameters on model outcomes 
was examined using probabilistic sensitivity analyses. Results: In the base-case 
model, treatment with afatinib was least expensive, with lifetime cost of $38,406, 
followed by cisplatin/pemetrexed ($40,714), and erlotinib ($41,344). Survival was 
highest with erlotinib (5.27 quality-adjusted life-months saved [QALMS]), followed 
by afatinib (4.02 QALMS), and cisplatin/pemetrexed (3.51 QALMS). Compared 
to erlotinib, afatinib had lower monthly drug costs ($5,648 versus $5,853), but 
higher overall side effects costs ($3,669 versus $1,690). Cisplatin/pemetrexed 
was dominated by afatinib. Erlotinib was cost-effective compared with afatinib 
(ICER= $28,210/QALYS). In a model without survival adjustments, afatinib com-
pared with erlotinib had an ICER over the WTP threshold (ICER= $542,745/QALYS), 
with erlotinib remaining the cost-effective option. Afatinib becomes more cost-
effective than erlotinib when its monthly drug cost decreased from $5,648 to below 
$3,802. ConClusions: Based on our analyses, we recommend erlotinib as the 
most cost-effective first-line treatment for EGFR-mutation positive NSCLC. Given 
the potentially similar relative efficacy between afatinib and erlotinib in the clini-
cal trials, cost-effectiveness analysis of afatinib versus erlotinib depends mostly 
on differences in drug and side-effects costs. Thus, afatinib may need to earn its 
share of the NSCLC market space with more competitive pricing.
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Cost-EffECtivENEss of ArsENiC trioxidE iN thE trEAtmENt of 
rElAPsEd/rEfrACtory ACutE PromyEloCytiC lymPhomA lEuKEmiA iN 
CANAdA
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objeCtives: Acute promyelocytic leukemia (APL) constitutes a rare disease char-
acterized by a high mortality rate at early stage of treatment. Current first-line 
treatments consist of all-trans retinoic acid (ATRA), anthracyclines and conventional 
chemotherapy (CT). Although APL has currently a good prognosis, 20 to 30% of 
patients who achieved remission still relapse and are further resistant to the treat-
ment previously administrated. The objective of this study was to assess, from a 
Canadian perspective, the economic impact of arsenic trioxide (ATO) compared to 
ATRA+CT in the treatment of relapsed/refractory APL. Methods: The cost-effec-
tiveness of ATO compared to ATRA+CT in the treatment of relapsed/refractory APL 
was assessed over a lifetime horizon using a time-dependent Markov model. The 
model comprises five health states: induction, second remission, treatment failure 
or relapse, post-failure, and death. The length of each Markov cycle was one month 
for the first 24 months and one year thereafter. All patients started in the induction 
state and could move to other health states thereafter, according to the respective 
efficacy of each treatment. The model also takes into account the incidence of 
grade 3-4 adverse events reported in clinical trials. Utility or disutility values associ-
ated with each health state and adverse events were used to estimate the number 
of QALYs associated with each treatment. Analyses were conducted from both a 
Canadian Ministry of Health (MoH) and a societal perspective. Results: Compared 
with ATRA+CT, ATO was associated with incremental cost-effectiveness ratios of 
$18,380/QALY from a MoH perspective and $20,156/QALY from a societal perspec-
tive. Results of the probabilistic sensitivity analysis indicated that ATO remains a 
cost-effective strategy in 99.96% and 92.45% of the simulations, from a MoH and a 
societal perspective respectively. ConClusions: This economic evaluation sug-
gests that ATO is a cost-effective strategy compared to ATRA+CT in the treatment 
of relapsed/refractory APL in Canada.
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Cost-EffECtivENEss ANAlysis of iNNovAtioN iN hEmAtologiC 
mAligNANCiEs
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objeCtives: To examine the costs of hematologic malignancies (HMs) in relation 
to survival gains among Medicare beneficiaries. Methods: Using the Surveillance, 
Epidemiology, and End Results (SEER)-Medicare datasets, we identified 99,721 
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A Cost EffECtivENEss ANAlysis of 4 ChEmothErAPy rEgimENs iN thE 
trEAtmENt of PlAtiNum sENsitivE rECurrENt EPithEliAl ovAriAN 
CArCiNomA
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objeCtives: Compare the cost effectiveness of 4 chemotherapy treatments for 
platinum-sensitive recurrent epithelial ovarian carcinoma (EOC). Methods: A 
Markov model was constructed using a hypothetical cohort of 500 women (median 
age 60) to compare 4 NCCN recommended treatment-regimens for platinum sensi-
tive recurrent EOC: carboplatin/paclitaxel (C/P); carboplatin/gemcitabine (C/G), C/G 
with bevacizumab (C/G+B); and carboplatin/pegylated liposomal doxorubicin (C/
PLD). These treatments were chosen as they are each supported by phase III trials. 
An indirect treatment comparison methodology was used to obtain evidence of the 
difference in treatment effects of each regimen. Progression free survival (PFS) and 
overall survival (OS) data were used for survival comparisons. The time horizon was 
thirty years. Cost calculations were based on data from Medicare and published 
literature, and were based on median cycle number from each trial. Published values 
of health utilities were used for QALY calculations. Cost effectiveness ratios (CER) 
were calculated for each regimen, and expressed as 3 incremental cost effectiveness 
ratios (ICER): additional month PFS, month OS, and QALY. Reported rates of grade 3/4 
toxicities from each trial were added to the cost of each treatment. Cost, survival, 
and toxicity rate were varied over a range for sensitivity analysis. Results: C/G 
was a cost-effective regimen. The cost for treating 1 woman with 6 cycles of C/G 
ranged from $1,140 (no toxicity) to $7,030 (toxicities at the reported rate). Treatment 
with C/G produced a dominant ICER of $236,318/month-PFS. For each PFS-month 
gained over the next most cost-effective option, over $200,000 was saved. C/G was 
the dominant strategy for OS, (ICER= $72,213/month OS). When adjusted for health 
utility, C/G was the dominant strategy (ICER of $20,443/QALY). ConClusions: C/G 
was a cost-effective regimen, resulting in a dominant ICER for PFS, OS, and QALY. C/G 
resulted in a savings compared to the next most cost effective regimen.
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mobiliziNg Autologous hEmAtoPoiEtiC stEm CElls iN PAtiENts 
with myElomA: A ECoNomiC ComPArisoN of 4 CommoN mobilizAtioN 
strAtEgiEs
Tay J., Sheppard D., Bredeson C., Allan D., Coyle D.
University of Ottawa, Ottawa, ON, Canada
objeCtives: Autologous stem cell transplantation (ASCT) is an integral part in the 
management of Multiple Myeloma (MM), the 2nd most common blood cancer. The 
collection of self stem cells – mobilization is required for ASCT. The optimal approach 
to procurement of stem cells remains debatable, with multiple competing clinical, 
cost and transplant-centre factors. In order to rationalize a preferred collection 
strategy we sought to perform a cost-effectiveness analysis from a Funder’s perspec-
tive of 4 common mobilization strategies used in Canada: Cyclophosphamide/G-CSF 
(Strategy 1), G-CSF alone (Strategy 2), Upfront-use of Plerixafor (Strategy 3), and “Just-
in-time” use of Plerixafor (Strategy 4). Methods: Clinical data was derived from 
published systematic reviews, randomized trials and observational studies. Further, 
a local audit was performed to evaluate external validity of the published data. 
Costing data for SC collection and adverse events were derived locally, The Ottawa 
Hospital. All unsuccessful 1st attempts with each strategy were assumed to be fol-
lowed by plerixafor re-mobilization. Probabilistic sensitivity analysis around costs 
and collection probabilities were varied simultaneously across their plausible range 
of values using Monte Carlo simulations (MCS). Results: Successful collection 
rates were 94.5%, 88.3%, 97.8% and 98.0% respectively for Strategies 1-4, with rates 
of adverse event of febrile neutropenia of 25.7%, 0%, 0% and 0%. Costs/patient were 
estimated as $8649, $9098, $17,309 and $13,119 respectively. Strategy 1 dominated 
strategy 2 in terms of cost and successful mobilization. The incremental cost per 
successful mobilization was $137,000 for strategy 4 vs. 1 and $1.6 million for strat-
egy 4 vs. 3. MCS found that the probability that strategy 4 was most successful was 
70.6%. Strategy 1 was least costly in 72.6% of simulations. ConClusions: Within 
the constraints of our model, our analyses suggest that Cyclophosphamide/G-CSF 
is a reasonable stem cell mobilization strategy in patients with myeloma requiring 
an ASCT, balancing costs and successful mobilization.
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objeCtives: Melanoma is one of the fastest growing cancers worldwide and prog-
nosis is poor with metastases. In about 50% of melanoma patients the BRAFV600 
protein kinase mutation is present. Two BRAFV600 targeted therapies dabrafenib 
(Tafinlar®) and vemurafenib (Zelboraf®), have recently received U.S. approval to 
treat metastatic melanoma in BRAFV600patients. This study evaluated the cost-
effectiveness of BRAF inhibitors compared to traditional chemotherapy (dacar-
bazine). Methods: A Markov model was developed with three health states: stable 
disease, progression, and death and taking a lifetime societal perspective. Transition 
probabilities and clinical outcomes were derived from Phase III trials. Costs were 
in 2013 USD and derived from literature, national databases, and Medicare fees. 
Utilities for melanoma and other health states were obtained from studies con-
ducted on the general public. Deterministic and probabilistic sensitivity analyses 
were run to test the impact of uncertainties. Results: Cumulative cost of dacar-
bazine, dabrafenib and vemurafenib respectively were $15,282, $43,895, and $59,768. 
Monthly Drug costs were respectively $537, $7,570, and $10,807. Effectiveness of 
dacarbazine, vemurafenib and dabrafenib were 0.37, 0.5 and 0.52 LY, respectively and 
quality adjusted were 0.22, 0.35 and 0.39 QALY. The incremental cost-effectiveness 
ratio was $14,569 per QALY for dabrafenib compared to dacarbazine. Dabrafenib 
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objeCtives: Italian recommendations for human papillomavirus (HPV) immu-
nization currently consider females only. However, males can be vectors in viral 
transmission and at risk of infection. The BEST II study was designed to evaluate: 
the cost-effectiveness (CE) of different interventions targeting females as well as 
males; and the economic impact of vaccination on a wide range of HPV-induced dis-
eases. Methods: A dynamic Bayesian Markov model was developed to investigate 
the transmission between sexual partners and the cost-effectiveness of vaccination 
targeting female and male cohorts in comparison to screening and female cohorts 
only. A range of HPV-induced diseases was considered (cervical, vaginal, vulvar, 
anal, head and neck and penile cancer, the associated pre-cancerous stages and 
anogenital warts). The process of sexual mixing was calculated based on age, gender 
and sexual behavioural specific matrices to estimate th force of infection dynami-
cally. Increased susceptibility to the virus, associated with early sexual début, a high 
number of partners, smoking and previous STDs, were included. We considered 
several scenarios; the baseline assumes universal vaccination to be implemented 
for 12-year-old females and males. The follow-up period was 55 years. Results: 
According to our preliminary analysis, universal vaccination resulted in incremental 
CE ratios (ICERs) corresponding to € 910 and € 5,770, when compared to screening-
only and female-only vaccination, respectively. We performed extensive sensi-
tivity analysis, which confirmed the good CE profile of universal vaccination in 
Italy. ConClusions: A universal HPV vaccination of male and female programme 
is more cost-effective than screening and female-only vaccination when account-
ing for all HPV-related diseases. Universal vaccination programme increase herd 
immunity and provide indirect protection to unvaccinated girls against HPV. The 
herd immunity plays a significant role in the economic evaluation of HPV immuni-
zation programmes. A universal vaccination may be further useful considering that 
males are both at risk of infection and vectors in viral transmission.
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Cost-EffECtivENEss ANAlysis of bENdAmustiNE-rituximAb trEAtmENt 
ComPArEd with fludArAbiNE-rituximAb trEAtmENt, iN PAtiENts with 
iNdolENt NoN-hodgKiN’s lymPhomA iN CostA riCA
Desanvicente-Celis Z.1, Obando C.A.1, Chaves M.1, Gonzalez L.2, Muschett D.1
1Janssen, Panama City, Panama, 2Janssen, Raritan, NJ, USA
objeCtives: To assess the cost-effectiveness of Bendamustine-Rituximab (BR) 
compared with Fludarabine-Rituximab (FR) treatment, in patients with Indolent 
Non-Hodgkin’s Lymphoma (INHL) that have progressed during or within six 
months of treatment with Rituximab or a Rituximab-containing Regimen in Costa 
Rica. Methods: A three-health state cohort simulation Markov Model (progres-
sion-free, progressive disease, and death) was developed based on time-dependent 
progression-free survival and overall survival data. The time frame was lifetime (35 
years). The perspective was that of the National Health System of Costa Rica. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs), Life Years 
(LYs), and Progression-free Life Years (PFLYs). Resource consumption for health 
states was elicited with the support of Latin American hematologists. Utilities for 
health states and disutility for adverse reactions were taken from published studies. 
All costs and Incremental Cost Effectiveness Ratios (ICERs) are presented in Costa 
Rican currency (Colones). Costs and outcomes were discounted at 3%. One way 
and probabilistic sensitivity (PSA) analysis were performed. Results: BR resulted 
in 4,641 QALYs/ 6,432 LYs/ and 3,564 PFLYs, per patient, respectively. FR resulted in 
3,557 QALYs/5,138 LYs and 2,047 PFLYs, per patient, respectively. Total costs were: 
76.309.813 for BR and 73.045.490 for FR. ICERs were: 3.013.664 per QALY gained, 
2.523.307 per LY gained and 2.151.945 per PFLY gained. In all outcomes, results 
were highly sensitive to Hazard Ratio of overall survival. According to the PSA, 
with QALYs as outcome, BR had a probability of 63% of being cost effective when 
considering the threshold of 3 times the Gross Domestic Product per capita (GDPPC) 
of Costa Rica (14.140.792). ConClusions: BR can be considered very cost-effective 
compared with FR in the study population (INHL) in Costa Rica, according to the 
threshold suggested by the World Health Organization [very cost effective below 
1 GDPPC (4.713.597)].
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rEANAlysis of Cost-EffECtivENEss of AbirAtEroNE ACEtAtE As sECoNd 
liNE trEAtmENt for mEtAstAtiC CAstrAtioN-rEsistANt ProstAtE 
CANCEr iN JAPAN usiNg A JAPANEsE ClAim dAtA sEt
Shibahara H.1, Shiroiwa T.2, Tange C.1, Nakamura K.1, Ozono S.3, Shimozuma K.1
1Ritsumeikan University, Kusatsu, Japan, 2Okayama University Hospital, Okayama, Japan, 
3Hamamatsu University, Hamamatsu, Japan
objeCtives: The objective of this study is to evaluate cost-effectiveness of abirater-
one plus prednisolone compared to prednisolone alone in Japan. We presented the 
result of the cost-effectiveness analysis of abiraterone acetate in 2013 ISPOR Europe 
Congress. In the present study we reanalyze the cost-effectiveness of abiraterone 
by referencing the real world resources using a Japanese claim data set. Methods: 
Cost-effectiveness analysis was performed using a Markov model based on data 
from the randomized controlled trial (COU-AA-301 study) and literature review 
conducted from the public health care payer’s perspective. The abiraterone plus 
prednisolone was compared with prednisolone alone. The base case was assumed 
to be a 72 year-old man with metastatic castration-resistant prostate cancer (CRCP). 
The model used a time horizon of 10 years. Outcomes were measured in quality-
Medicare beneficiaries aged ≥ 66 diagnosed with HM between January 1, 1995 and 
December 31, 2007, including: acute myeloid leukemia (AML, n= 10,173); chronic lym-
phocytic leukemia (CLL, n= 13,743); chronic myelogenous leukemia (CML, n= 4,169); 
Hodgkin lymphoma (HL, n= 2,252); non-Hodgkin lymphoma (NHL, n= 51,087); and 
multiple myeloma (MM, n= 18,297). We used a discrete hazard model to estimate 
survival and projected lifetime costs using a generalized linear model with a log-
link and gamma distribution. Models were adjusted for year of diagnosis, age, race, 
gender, and comorbidity. We calculated the incremental cost-effectiveness ratio 
(ICER, measured in terms of cost per life year [LY]) using cost and survival differences 
between the earliest (1995-1998) and latest (2005-2007) time periods. Costs were 
standardized to year 2010 dollars. Results: HM survival among Medicare patients 
increased during the time period studied, though gains varied by diagnosis. Care 
costs for all diagnoses also increased over time, especially for HL (from $148,000 
for individuals diagnosed during 1995-1998 to $230,000 for a 2005-2007 diagnosis) 
and NHL (from $158,000 for patients diagnosed during 1995-1998 to $247,000 for 
a 2005-2007 diagnosis). Survival gains were most cost-effective for CML ($37,877/
LY) and least cost-effective for HL ($94,859/LY). The ICERs were $43,262/LY for CLL, 
$59,355/LY for MM, $62,127/LY for NHL, and $83,392/LY for AML. ConClusions: Our 
findings suggest that over a period of more than a decade, improvements in treat-
ment for HM have been associated with gains in survival, but also with substantial 
increases in health care costs. Overall, HM therapy innovations appear to provide 
good value for money among Medicare patients when evaluated using conventional 
cost-effectiveness metrics.
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objeCtives: Sunitinib is one of the first targeted treatments for metastatic renal 
cell carcinoma (MRCC) and is currently considered as the standard of care for 
most of the MRCC patients in the first-line setting. Sunitinib delays disease pro-
gression, with a median overall survival of more than 2 years, improves quality 
of life and is becoming the first-line standard of care for MRCC. The introduction 
of targeted treatments, led to improvements in disease management and sur-
vival of these patients, however, with increasing cost. Purpose this reserch - to 
assess the economic value of sunitinib as first-line therapy in MRCC within the 
Kazakh health care system. Methods: Cost-effectiveness of sunitinib has been 
assessed on several occasions and a systematic literature search was conducted 
to find all published research articles as well as all research abstracts presented 
in various congresses. An adapted Markov model with a 10-year time horizon 
was used to analyse the cost effectiveness of sunitinib vs. sorafenib (SFN) and 
bevacizumab/interferon-α (BEV/IFN) as first-line MRCC therapy from the Kazakh 
perspective. Results: Progression-free survival and overall survival data from 
sunitinib, SFN and BEV/IFN pivotal trials were extrapolated to project survival 
and costs in 6-week cycles. Results, in progression-free life-years (PFLY), life 
years (LY) and quality-adjusted life-years (QALY) gained, expressed as incremen-
tal cost-effectiveness ratios (ICER) with costs and benefits discounted annually 
approximate 3%, were obtained using deterministic and probabilistic analyses. 
Sunitinib was more effective and less costly than both SFN and BEV/IFN with 
average cost savings/patients, respectively. Using a willingness-to-pay threshold, 
sunitinib achieved an incremental net benefit compared with SFN and BEV/IFN, 
respectively. At this willingness-to-pay, the probability of sunitinib providing the 
highest incremental net benefit was 72%. ConClusions: Our analysis suggests 
that sunitinib is a costeffective alternative to other targeted therapies as first-line 
MRCC therapy in the Kazakh health care setting.
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Cost EffECtivENEss ANAlysis of AddiNg rAdiAtioN thErAPy to 
ANdrogEN dEPrivAtioN thErAPiEs iN mEN with loCAlly AdvANCEd 
ProstAtE CANCEr iN thE uNitEd stAtEs
Upadhyay N.
University of Houston, HOUSTON, TX, USA
objeCtives: Whether the addition of radiation therapy (RT) improves overall 
cost effectiveness in men with locally advanced prostate cancer managed with 
androgen deprivation therapy (ADT) is still unclear. Our objective was to conduct 
cost-effectiveness analysis of adding radiation therapy to androgen deprivation 
therapies in men with locally advanced prostate cancer in the U.S.A. Methods: A 
decision analysis model was designed to compare adding RT to ADT over a 10 year 
time horizon with the third party payer’s perspective. Probabilities of treatment 
success, utilization of salvage treatments, and rates of adverse events were taken 
from published results of SPCG-7/SFUO-3 trial and NCIC CTG PR.3/MRC UK PR07 
trial. Cost inputs were based on 2010 Medicare reimbursement rates and reported 
in 2013 US dollars. Primary outcome measure was incremental cost per biochemi-
cal success (i.e. serum PSA level < 0.4 ng/ml). 50,000 U.S. dollars were considered 
willingness to pay threshold. A series of one-way sensitivity analyses and Monte 
Carlo simulation was performed by testing variations in the range of the 95% con-
fidence interval. Results: ART results in a higher biochemical success rate than 
hormonal therapy with a probability of 0.30 versus 0.21. The mean incremental 
effect was 0.6 over a 10-year period. Total cost of ART was $25,783 compared with 
costs in the ADT group of $13,427 per year, the mean incremental cost for ART ver-
sus ADT was $8,277 over 10 year period. The mean incremental cost effectiveness 
ratio was $13758 over 10 year period. Cost-effectiveness acceptability curve analysis 
resulted in > 90% probability that ART with hormonal therapy is cost-effective strat-
egy. ConClusions: Study suggests that adding RT to ADT is cost effective strategy 
compared to ADT alone based upon the decision analysis model for appropriate men 
with locally advanced prostate cancer. The study limitations and treatment dosage 
should be considered before applying the results of the study.
